Ascletis' ASC30 obesity drug shows 75-day half-life in US Study
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Element5’s Agentic AI platform will be integrated with the HCHB EHR
The discussions are expected to pave the way for the creation of a consolidated national knowledge-sharing platform on IT-enabled Ayush services,
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
Maria Soler Nunez appointed as Chief Quality Officer
Mansam, founded in 2022, is positioned as the first Arabian luxury fragrance brand with a vision for global expansion
Subscribe To Our Newsletter & Stay Updated